- Investing Ideas
- /
- Hong Kong Pharmaceuticals & Biotech Financially Fit Penny Stocks
Hong Kong Pharmaceuticals & Biotech Financially Fit Penny Stocks
Results
18
A Penny Stocks screener, typically smaller or younger companies trading at a price below 5, with a focus on solid financial health that should present companies with a lower risk profile than other early-stage businesses
18 companies
JBM (Healthcare)
Market Cap: HK$2.4b
An investment holding company, engages in the manufacture, marketing, distribution, and sale of branded healthcare and wellness products in Hong Kong, Macau, Mainland China, and internationally.
2161
HK$2.93
7D
-5.2%
1Y
208.4%
Tong Ren Tang Technologies
Market Cap: HK$6.1b
Produces and distributes Chinese medicine products in Mainland China and Hong Kong.
1666
HK$4.79
7D
-2.6%
1Y
-11.1%
SSY Group
Market Cap: HK$8.5b
An investment holding company, researches, develops, manufactures, trades in, and sells various pharmaceutical products to hospitals and distributors in the People’s Republic of China and internationally.
2005
HK$2.90
7D
-2.0%
1Y
-28.7%
Pak Fah Yeow International
Market Cap: HK$772.9m
An investment holding company, engages in manufacturing, marketing, and distributing healthcare products under the Hoe Hin brand name.
239
HK$2.48
7D
-2.7%
1Y
2.1%
Jilin Province Huinan Changlong Bio-pharmacy
Market Cap: HK$1.2b
Manufactures and distributes Chinese medicines and pharmaceutical products in the People’s Republic of China.
8049
HK$2.14
7D
-1.4%
1Y
62.1%
Dawnrays Pharmaceutical (Holdings)
Market Cap: HK$1.8b
An investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally.
2348
HK$1.21
7D
0%
1Y
6.1%
Lee's Pharmaceutical Holdings
Market Cap: HK$1.4b
An investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally.
950
HK$2.30
7D
-7.3%
1Y
93.3%
Frontage Holdings
Market Cap: HK$2.5b
A contract research organization, provides laboratory and related services to pharmaceutical, biotechnology, and agrochemical companies.
1521
HK$1.25
7D
-6.0%
1Y
66.7%
Uni-Bio Science Group
Market Cap: HK$889.7m
An investment holding company, researches and develops, manufactures, and sells biological and chemical pharmaceutical products to treat human diseases in the People’s Republic of China.
690
HK$0.15
7D
-2.0%
1Y
93.5%
Viva Biotech Holdings
Market Cap: HK$5.1b
An investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide.
1873
HK$2.41
7D
-6.6%
1Y
213.0%
JW (Cayman) Therapeutics
Market Cap: HK$1.7b
A clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People’s Republic of China.
2126
HK$4.10
7D
-17.7%
1Y
159.5%
China Health Group
Market Cap: HK$190.1m
An investment holding company, researches and develops drugs, bio drugs, natural drugs, and synthetic drugs in the People’s Republic of China.
8225
HK$0.19
7D
20.9%
1Y
59.2%
Genor Biopharma Holdings
Market Cap: HK$1.9b
A biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally.
6998
HK$3.71
7D
-9.3%
1Y
n/a
Biosino Bio-Technology and Science Incorporation
Market Cap: HK$124.4m
Manufactures, sells, and distributes in-vitro diagnostic reagents in Mainland China.
8247
HK$0.86
7D
-10.4%
1Y
28.4%
AIM Vaccine
Market Cap: HK$4.9b
Engages in the research and development, manufacture, and sale of vaccine products for human use in the People’s Republic of China.
6660
HK$3.99
7D
-8.7%
1Y
-30.2%
Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd
Market Cap: HK$8.1b
Engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China.
1349
HK$3.47
7D
-7.7%
1Y
60.6%
Brii Biosciences
Market Cap: HK$1.3b
Focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States.
2137
HK$1.87
7D
-9.2%
1Y
59.8%
Kintor Pharmaceutical
Market Cap: HK$1.1b
A clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology in the People’s Republic of China.
9939
HK$2.38
7D
-11.2%
1Y
118.3%